US Patent 11596669 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
Patent 11596669 was granted and assigned to 89Bio on March, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 27 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Apr, 2023
Golden AI
Infobox
Edits on 26 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115966690
Date of Patent
March 7, 2023
0Patent Application Number
176920240
Date Filed
March 10, 2022
0Patent Primary Examiner
Edits on 8 Mar, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Article (+299 characters)
US Patent 11596669 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
Article
The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115966690
Date of Patent
March 7, 2023
0Patent Application Number
176920240
Date Filed
March 10, 2022
0Patent Primary Examiner
Find more entities like US Patent 11596669 Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
